1. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. [
DOI:10.1007/s11906-018-0812-z] [
PMID] [
]
2. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6-10. [
DOI:10.1016/j.metabol.2018.09.005] [
PMID]
3. Czerwińska M, Czarzasta K, Cudnoch-Jędrzejewska A. New Peptides as Potential Players in the Crosstalk Between the Brain and Obesity, Metabolic and Cardiovascular Diseases. Front Physiol. 2021;12:692642. [
DOI:10.3389/fphys.2021.692642] [
PMID] [
]
4. Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M, Mrugacz M. Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications. Int J Mol Sci. 2020;21(10):3570. [
DOI:10.3390/ijms21103570] [
PMID] [
]
5. Landecho MF, Tuero C, Valentí V, Bilbao I, de la Higuera M, Frühbeck G. Relevance of Leptin and Other Adipokines in Obesity-Associated Cardiovascular Risk. Nutrients. 2019;11(11):2664. [
DOI:10.3390/nu11112664] [
PMID] [
]
6. Al-Lami HB, Al-Tu'ma F J, Al-Safi WG. Association between anti-Müllerian hormone and other biomarkers with ovarian function in polycystic ovarian syndrome of Iraqi women. J Contemp Med Sci. 2020;6(4). [
DOI:10.22317/jcms.v6i4.824]
7. Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2019;92:108-120. [
DOI:10.1016/j.metabol.2018.11.002] [
PMID]
8. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618. [
DOI:10.1093/humrep/dey256] [
PMID] [
]
9. Moran LJ, Tassone EC, Boyle J, Brennan L, Harrison CL, Hirschberg AL, et al. Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: Lifestyle management. Obes Rev. 2020;21(10):e13046. [
DOI:10.1111/obr.13046] [
PMID]
10. Polak AM, Adamska A, Krentowska A, Łebkowska A, Hryniewicka J, Adamski M, Kowalska I. Body Composition, Serum Concentrations of Androgens and Insulin Resistance in Different Polycystic Ovary Syndrome Phenotypes. J Clin Med. 2020;9(3):732. [
DOI:10.3390/jcm9030732] [
PMID] [
]
11. Mumusoglu S, Yildiz BO. Polycystic ovary syndrome phenotypes and prevalence: Differential impact of diagnostic criteria and clinical versus unselected population. Curr Opin Endocr Metab Res. 2020;12:66-71. [
DOI:10.1016/j.coemr.2020.03.004]
12. Tutunchi H, Ostadrahimi A, Hosseinzadeh-Attar MJ, Miryan M, Mobasseri M, Ebrahimi-Mameghani M. A systematic review of the association of neuregulin 4, a brown fat-enriched secreted factor, with obesity and related metabolic disturbances. Obes Rev. 2020;21(2):e12952. [
DOI:10.1111/obr.12952] [
PMID]
13. Gumà A, Martínez-Redondo V, López-Soldado I, Cantó C, Zorzano A. Emerging role of neuregulin as a modulator of muscle metabolism. Am J Physiol Endocrinol Metab. 2010;298(4):E742-50. [
DOI:10.1152/ajpendo.00541.2009] [
PMID]
14. Liu Y, Chen M. Neuregulin 4 as a novel adipokine in energy metabolism. Front Physiol. 2023;13:1106380. [
DOI:10.3389/fphys.2022.1106380] [
PMID] [
]
15. Chen W, Pang Y. Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. Metabolites. 2021;11(12):869. [
DOI:10.3390/metabo11120869] [
PMID] [
]
16. Bahadur A, Verma N, Mundhra R, Chawla L, Ajmani M, Sri MS, Arora S. Correlation of Homeostatic Model Assessment-Insulin Resistance, Anti-Mullerian Hormone, and BMI in the Characterization of Polycystic Ovary Syndrome. Cureus. 2021;13(6):e16047. [
DOI:10.7759/cureus.16047]
17. Ayoob LA. Evaluation of serum Neuregulin4 level in Polycystic ovary syndrome patients. Eurasian Med Res Period. 2022;13:7-10.
18. Kurek Eken M, Sahin Ersoy G, Yayla Abide C, Sanverdi İ, Devranoglu B, Kutlu T, Çevik Ö. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome. J Obstet Gynaecol. 2019;39(7):975-980 [
DOI:10.1080/01443615.2019.1581754] [
PMID]
19. Temur M, Calan M, Akşit M, Yılmaz Ö, Çift T, Akselim B, et al. Increased serum neuregulin 4 levels in women with polycystic ovary syndrome: A case-control study. Ginekol Pol. 2017;88(10):517-522. [
DOI:10.5603/GP.a2017.0095] [
PMID]
20. Cao S, Hu Y. Effects of serum irisin, neuregulin 4, and weight management on obese adolescent girls with polycystic ovary syndrome. Biosci Rep. 2021;41(9):BSR20211658. [
DOI:10.1042/BSR20211658] [
PMID] [
]
21. Li L, Feng Q, Ye M, He Y, Yao A, Shi K. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis. J Obstet Gynaecol. 2017;37(8):1036-1047. [
DOI:10.1080/01443615.2017.1318840] [
PMID]
22. Ariaee N, Farid R, Shabestari F, Shabestari M, Jabbari Azad F. Trace Elements Status in Sera of Patients with Allergic Asthma. Rep Biochem Mol Biol. 2016;5(1):20-25.
23. Shenta A, Saud K, Al-Shawi A. Assessment the Correlations of Hormones, Lipid Profiles, Oxidative Stress, and Zinc Concentration in Iraqi Women with Polycystic Ovary Syndrome. Rep Biochem Mol Biol. 2020;9(3):270-277. [
DOI:10.29252/rbmb.9.3.270] [
PMID] [
]